Company intelligence / Profile preview
Mabylon AG
Schlieren, Zurich, Switzerlandmabylon.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Mabylon AG develops fully human monoclonal antibodies using advanced B-cell screening technologies. Its lead program, MY006—a multi-specific antibody therapeutic targeting peanut allergy—has shown promising preclinical results in preventing anaphylaxis in animal models. The company has entered into a partnership with Pfizer Ignite to accelerate the development of its anti-peanut allergy candidate. Other pipeline programs target severe allergies, inflammatory conditions, and neurological disorders.
- Therapeutic areas
- ImmunologyNeurology
- Modalities
- monoclonal antibodies (mAbs)human-derived antibodies
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Pfizer Ignite (for expedited development of anti-peanut-allergy therapeutic)
Beyond the preview
Go deeper on Mabylon AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mabylon AG.